Paolo Tarantino, Research Fellow at the Dana-Farber Cancer Institute, shared a post on X:
“Impressive phase 2 data with the Trop2 ADC Sac-TMT for 1L mTNBC (n=41): ORR 70%, mPFS 13.4 months.
High activity irrespective of PDL1 expression. Same setting of ASCENT-03/04.
Confirms the feeling that, in the future, we’ll treat mTNBC with frontline Trop2 ADCs.”
More posts featuring ASCO 2025 on OncoDaily.
